Home

The Korea Herald

Latest news

Most Popular

  1. 1

    N. Korea decides to expel US soldier Travis King

    N. Korea decides to expel US soldier Travis King
  2. 2

    Is S. Korea dangerous for women?

    Is S. Korea dangerous for women?
  3. 3

    S. Korea holds rare military parade, warns NK against nuclear attack

    S. Korea holds rare military parade, warns NK against nuclear attack
  4. 4

    Do professors in Korea have too much power over students?

    Do professors in Korea have too much power over students?
  5. 5

    Lee Jae-myung's arrest reprieve emboldens opposition fightback

    Lee Jae-myung's arrest reprieve emboldens opposition fightback
  6. 6

    New teachers’ manual bans recording devices in classrooms

    New teachers’ manual bans recording devices in classrooms
  7. 7

    At 93 and on quest to become Korea's oldest Ph.D. grad

    At 93 and on quest to become Korea's oldest Ph.D. grad
  8. 8

    ‘Do you know Dr. Hong?’ Moms say they wish they didn’t

    ‘Do you know Dr. Hong?’ Moms say they wish they didn’t
  9. 9

    [KH Explains] Lotte goes all-out to secure cash amid lackluster earnings

    [KH Explains] Lotte goes all-out to secure cash amid lackluster earnings
  10. 10

    BTS agency likely to face tougher disclosure rules

    BTS agency likely to face tougher disclosure rules
지나쌤

Celltrion’s Remicade biosimilar nearing U.S. approval

By Sohn Ji-young

Published : Jan. 18, 2016 - 12:04

    • Link copied

Celltrion is drawing closer to launching its rheumatoid treatment Remsima in the U.S.

The company said Monday that the U.S. Food and Drug Administration is scheduled to hold a committee meeting Feb. 9 (local time) to review and discuss Remsima’s approval in the North American market.

Remsima is a biosimilar replication of Johnson & Johnson’s blockbuster rheumatoid arthritis treatment Remicade.

The entrance to Celltrion's headquarters in Incheon (Yonhap) The entrance to Celltrion's headquarters in Incheon (Yonhap)

The news prompted Celltrion shares to surge by 17.64 percent from the previous trading day, to close at 116,700 won on the secondary Korean bourse on Monday.

The meeting’s outcome will be significant since a positive recommendation from the committee is typically followed by legal approval by the U.S. FDA.

“Given that Remsima has already been approved in 67 countries including those in Europe, the biosimilar drug is expected to be approved in the U.S. as well,” said NH Investment & Securities analyst Lee Seung-ho.

Celltrion’s new drug is set to emerge as a new game changer in the U.S. arthritis treatment market, which takes up roughly 54.5 percent of Remicade’s entire sales globally.

As Remsima clinically proves its ability to treat additional symptoms including those related to inflammatory diseases, its original replacement rate is slated to further increase, raising Celltrion’s stock price in the process, according to Lee.

By Sohn Ji-young (jys@heraldcorp.com)

More from Headlines